BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 10982292)

  • 1. Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation.
    de Medeiros CR; Moreira VA; Pasquini R
    Bone Marrow Transplant; 2000 Aug; 26(4):443-4. PubMed ID: 10982292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy.
    Machado CM; Dulley FL; Boas LS; Castelli JB; Macedo MC; Silva RL; Pallota R; Saboya RS; Pannuti CS
    Bone Marrow Transplant; 2000 Aug; 26(4):413-7. PubMed ID: 10982288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring of CMV infection after bone marrow transplantation].
    Okada M; Takemoto Y
    Nihon Rinsho; 1998 Jan; 56(1):189-92. PubMed ID: 9465688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies.
    Couriel D; Canosa J; Engler H; Collins A; Dunbar C; Barrett AJ
    Bone Marrow Transplant; 1996 Aug; 18(2):347-53. PubMed ID: 8864445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
    Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N
    Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
    Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT.
    Machado CM; Menezes RX; Macedo MC; Mendes AV; Boas LS; Castelli JB; Dulley FL; Pannuti CS
    Bone Marrow Transplant; 2001 Dec; 28(11):1053-9. PubMed ID: 11781616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989.
    Atkinson K; Nivison-Smith I; Dodds A; Concannon A; Milliken S; Downs K
    Bone Marrow Transplant; 1998 Apr; 21(7):691-5. PubMed ID: 9578309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
    Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
    Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
    Nguyen Q; Champlin R; Giralt S; Rolston K; Raad I; Jacobson K; Ippoliti C; Hecht D; Tarrand J; Luna M; Whimbey E
    Clin Infect Dis; 1999 Mar; 28(3):618-23. PubMed ID: 10194088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation].
    Sakai R; Maruta A; Taguchi J; Tomita N; Fujita H; Kodama F; Ogawa K; Fujisawa S; Matsuzaki M; Motomura S; Okubo T
    Rinsho Ketsueki; 1996 Jan; 37(1):14-21. PubMed ID: 8683862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.
    Ljungman P; De Bock R; Cordonnier C; Einsele H; Engelhard D; Grundy J; Locasciulli A; Reusser P; Ribaud P
    Bone Marrow Transplant; 1993 Oct; 12(4):399-403. PubMed ID: 8275040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
    Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H
    Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation.
    Stocchi R; Szydlo R; Craddock C; Kanfer E; Apperley JF; Goldman JM; Ward KN
    Bone Marrow Transplant; 1999 Apr; 23(7):705-9. PubMed ID: 10218848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.